Sign inCreate account

Report workspace tools

NCT07339098NOT_YET_RECRUITINGanonymous

A Prospective, Multicenter, Single-arm, Open-label, Non-randomized Exploratory Clinical Trial to Evaluate the Efficacy and Safety of Glomerular Filtration Rate (GFR-EPI) Using NEFRONIX in Patients With Chronic Kidney Disease (CKD)

Sponsor

Source record

Anasonic

Phase

Source record

Exploratory (Not yet recruiting)

Modality

AI-normalized

medical device

Target

AI-normalized

Ultrasound stimulation of renal tissue to potentially enhance glomerular filtration rate (GFR) in patients with chronic kidney disease (CKD).

Indication / condition

AI-normalized

Chronic Kidney Disease

Intervention

Source record

Ultrasound Stimulation (NEFRONIX G-01)

Source & freshness

Source record

NCT ID

NCT07339098

Original source

ClinicalTrials.gov

Source last updated

Jan 15, 2026

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT07339098

Title

A Prospective, Multicenter, Single-arm, Open-label, Non-randomized Exploratory Clinical Trial to Evaluate the Efficacy and Safety of Glomerular Filtration Rate (GFR-EPI) Using NEFRONIX in Patients With Chronic Kidney Disease (CKD)

Sponsor

Anasonic

Status

NOT_YET_RECRUITING

Phase

Exploratory (Not yet recruiting)

Condition raw

Chronic Kidney Disease

Condition normalized

Chronic Kidney Disease

Modality raw

medical device

Modality normalized

medical device

Target raw

Ultrasound stimulation of renal tissue to potentially enhance glomerular filtration rate (GFR) in patients with chronic kidney disease (CKD).

Target normalized

Ultrasound stimulation of renal tissue to potentially enhance glomerular filtration rate (GFR) in patients with chronic kidney disease (CKD).

Interventions

Ultrasound Stimulation (NEFRONIX G-01)

Public preview

Source record

Anasonic's NEFRONIX G-01 device is positioned in the emerging market of non-invasive therapies for chronic kidney disease, a condition affecting millions globally. The exploratory nature of this trial may provide initial efficacy and safety data, which could support further development and potential regulatory pathways. Given the increasing prevalence of CKD and the limitations of current treatment options, successful outcomes could lead to significant market opportunities. However, the competitive landscape includes established pharmaceutical interventions and emerging technologies, necessitating a thorough competitive analysis and strategic positioning. Diligence should focus on the robustness of trial design, potential regulatory hurdles, and reimbursement pathways.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Prospective, Multicenter, Single-arm, Open-label, Non-randomized Exploratory Clinical Trial to Evaluate the Efficacy and Safety of Glomerular Filtration Rate (GFR-EPI) Using NEFRONIX in Patients With Chronic Kidney Disease (CKD)

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT07339098

Status

NOT_YET_RECRUITING

Phase

Exploratory (Not yet recruiting)

Sponsor

Anasonic

Executive brief

Investment-Ready Snapshot

Anasonic's NEFRONIX G-01 device is positioned in the emerging market of non-invasive therapies for chronic kidney disease, a condition affecting millions globally. The exploratory nature of this trial may provide initial efficacy and safety data, which could support further development and potential regulatory pathways. Given the increasing prevalence of CKD and the limitations of current treatment options, successful outcomes could lead to significant market opportunities. However, the competitive landscape includes established pharmaceutical interventions and emerging technologies, necessitating a thorough competitive analysis and strategic positioning. Diligence should focus on the robustness of trial design, potential regulatory hurdles, and reimbursement pathways.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJan 15, 2026
Internal syncJun 11, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT07339098

Indication

Chronic Kidney Disease

Modality

medical device

Target

Ultrasound stimulation of renal tissue to potentially enhance glomerular filtration rate (GFR) in patients with chronic kidney disease (CKD).

Intervention

Ultrasound Stimulation (NEFRONIX G-01)

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.